Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-6.13 Insider Own11.50% Shs Outstand26.60M Perf Week-4.63%
Market Cap653.22M Forward P/E- EPS next Y-6.30 Insider Trans-5.23% Shs Float24.18M Perf Month26.71%
Income-163.30M PEG- EPS next Q-0.96 Inst Own97.52% Short Float18.36% Perf Quarter-9.64%
Sales22.96M P/S28.45 EPS this Y2.97% Inst Trans4.80% Short Ratio11.84 Perf Half Y68.38%
Book/sh1.75 P/B13.67 EPS next Y-6.82% ROA-34.11% Short Interest4.44M Perf Year26.31%
Cash/sh12.98 P/C1.84 EPS next 5Y- ROE-136.73% 52W Range13.36 - 27.50 Perf YTD11.62%
Dividend Est.- P/FCF- EPS past 5Y-19.45% ROI-43.72% 52W High-13.05% Beta-0.31
Dividend TTM- Quick Ratio11.53 Sales past 5Y172.96% Gross Margin89.60% 52W Low78.97% ATR (14)1.43
Dividend Ex-Date- Current Ratio11.53 EPS Y/Y TTM-26.36% Oper. Margin-674.47% RSI (14)49.03 Volatility5.74% 6.82%
Employees117 Debt/Eq6.86 Sales Y/Y TTM114.78% Profit Margin-711.17% Recom1.60 Target Price43.78
Option/ShortYes / Yes LT Debt/Eq6.82 EPS Q/Q-3.54% Payout- Rel Volume0.73 Prev Close24.96
Sales Surprise79.43% EPS Surprise-4.71% Sales Q/Q422.49% EarningsMay 09 AMC Avg Volume374.97K Price23.91
SMA20-3.74% SMA504.43% SMA20015.67% Trades Volume271,939 Change-4.21%
Date Action Analyst Rating Change Price Target Change
Apr-16-24Initiated Leerink Partners Outperform $47
Apr-11-24Initiated Wells Fargo Overweight $56
Mar-12-24Upgrade Wedbush Neutral → Outperform $20 → $34
Feb-26-24Initiated BTIG Research Buy $55
Feb-21-24Initiated Stifel Buy $50
Feb-16-24Initiated Piper Sandler Overweight $80
May-22-23Upgrade JP Morgan Underweight → Neutral $31 → $30
May-18-23Initiated TD Cowen Outperform
Jan-06-23Downgrade Raymond James Outperform → Mkt Perform
Nov-01-22Upgrade Guggenheim Neutral → Buy $44
May-09-24 05:45PM
May-02-24 10:01AM
04:51AM Loading…
May-01-24 04:51AM
Apr-24-24 09:00AM
Apr-15-24 02:19PM
Apr-12-24 07:00PM
Apr-09-24 02:40PM
Mar-14-24 12:00PM
Mar-11-24 05:30PM
Feb-29-24 09:15AM
10:00AM Loading…
Feb-28-24 10:00AM
Feb-22-24 04:00AM
Feb-19-24 05:54AM
Jan-31-24 09:15AM
Jan-12-24 03:02PM
Dec-07-23 09:55AM
Nov-27-23 04:15PM
Nov-14-23 09:35AM
Nov-07-23 04:15PM
Nov-04-23 05:41AM
Nov-02-23 04:15PM
Nov-01-23 09:15AM
Oct-11-23 09:15AM
Oct-09-23 08:27AM
08:05AM Loading…
Sep-19-23 03:01PM
Sep-18-23 04:15PM
Sep-12-23 09:15AM
Aug-07-23 04:15PM
Jul-31-23 01:34PM
Jul-04-23 06:22AM
May-30-23 04:15PM
May-24-23 06:01AM
May-22-23 01:44AM
May-11-23 05:35PM
May-04-23 09:55AM
May-02-23 09:15AM
Apr-30-23 09:47AM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-14-23 03:13AM
Apr-06-23 04:15PM
Apr-03-23 07:14AM
Mar-27-23 06:50PM
Mar-01-23 05:45PM
Feb-27-23 04:05PM
Jan-13-23 09:00AM
Jan-05-23 04:05PM
Dec-22-22 09:33AM
Dec-02-22 09:00AM
Nov-21-22 01:56PM
Nov-11-22 05:19AM
Nov-09-22 02:10PM
Nov-08-22 05:55PM
Oct-25-22 06:28AM
Oct-13-22 09:55AM
Oct-06-22 11:02AM
Oct-05-22 11:31AM
Sep-26-22 08:00AM
Sep-19-22 02:02PM
Sep-14-22 06:14AM
Sep-12-22 11:18AM
Sep-02-22 01:41PM
Sep-01-22 09:58AM
Aug-31-22 04:15PM
Aug-10-22 06:28AM
Aug-08-22 05:35PM
Aug-05-22 04:00PM
Jul-08-22 07:22AM
Jun-24-22 06:31AM
Jun-02-22 04:05PM
May-10-22 06:09AM
May-04-22 06:55PM
Apr-28-22 08:48AM
Apr-27-22 04:15PM
Apr-26-22 07:05AM
Mar-21-22 04:15PM
Mar-15-22 11:35AM
Mar-14-22 04:20PM
Mar-09-22 05:09AM
Mar-07-22 10:05AM
Feb-17-22 03:02PM
Jan-21-22 10:49AM
Jan-19-22 10:46AM
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MULROY DENNISCHIEF FINANCIAL OFFICERMay 22 '24Sale23.721,50035,580964May 24 04:12 PM
Faga DanielCEOMar 25 '24Sale21.423,00064,268749,087Mar 26 08:10 PM
Faga DanielCEOMar 22 '24Sale22.78145,9403,325,185752,087Mar 26 08:10 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 16 '24Option Exercise14.025,00070,1008,240Feb 21 05:38 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 16 '24Sale25.005,000125,0003,240Feb 21 05:38 PM
MULROY DENNISCHIEF FINANCIAL OFFICERJan 30 '24Sale23.633,06572,425964Feb 01 05:27 PM
Faga DanielCEOJan 08 '24Sale21.816,866149,747898,027Jan 09 07:05 PM
Lizzul Paul F.Chief Medical OfficerJan 08 '24Sale21.812,55455,70310,118Jan 09 07:08 PM
LOUMEAU ERIC JChief Legal OfficerJan 08 '24Sale21.812,30550,2723,240Jan 09 07:07 PM
MULROY DENNISChief Financial OfficerJan 08 '24Sale21.812,18047,5464,029Jan 09 07:06 PM
LOUMEAU ERIC JChief Legal OfficerJan 06 '24Option Exercise0.005,54505,545Jan 09 07:07 PM
Lizzul Paul F.Chief Medical OfficerJan 06 '24Option Exercise0.006,145012,672Jan 09 07:08 PM
MULROY DENNISChief Financial OfficerJan 06 '24Option Exercise0.005,24506,209Jan 09 07:06 PM
Faga DanielCEOJan 06 '24Option Exercise0.0017,8500904,893Jan 09 07:05 PM
LOUMEAU ERIC JChief Legal OfficerNov 22 '23Sale14.1988212,5160Nov 27 04:03 PM
MULROY DENNISChief Financial OfficerSep 18 '23Sale19.323,89575,237964Sep 18 06:12 PM
LOUMEAU ERIC JChief Legal OfficerSep 18 '23Sale19.323,89575,232882Sep 18 06:13 PM
Lizzul Paul F.Chief Medical OfficerSep 14 '23Sale19.482,10541,0056,527Sep 18 06:14 PM
LOUMEAU ERIC JChief Legal OfficerSep 14 '23Sale19.482,10541,0054,777Sep 18 06:13 PM
MULROY DENNISChief Financial OfficerSep 14 '23Sale19.482,10541,0054,859Sep 18 06:12 PM